Results 11 to 20 of about 5,430 (178)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection

Bangladesh Journal of Pharmacology, 2017
Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes.
Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Mohamed Gadelkarim, Arwa Mohamed, Mohamed Gabr, Ahmed Negida   +5 more
doaj   +3 more sources

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C [PDF]

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +2 more sources

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in ...
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina   +13 more
doaj   +3 more sources

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015
The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin   +2 more
doaj   +2 more sources

Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK-Based Therapy. [PDF]

Health Sci Rep
ABSTRACT Background Hepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV
Joukar F, Yeganeh S, Eslami N, Mansour-Ghanaei F.   +3 more
europepmc   +2 more sources

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis

Therapeutics and Clinical Risk Management, 2017
Jan Sperl,1 Sona Frankova,1 Miluse Kreidlova,2 Dusan Merta,3 Monika Tothova,4 Julius Spicak1 1Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 2Institute of Medical Biochemistry and Laboratory Medicine, General ...
Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J   +5 more
doaj   +1 more source

Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan.
Shah S, Mafirakureva N, Trickey A, Hasnain A, Khan U, Khowaja S, Ashraf H, Baig-Ansari N, Hickman M, Vickerman P, Walker JG, Lim AG.   +11 more
europepmc   +2 more sources

Sofosbuvir and daclatasvir [PDF]

British Journal of Clinical Pharmacology, 2016
Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel, Adam F. Cohen, Robert Rissmann   +2 more
openaire   +2 more sources

Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome

Biomedical and Biotechnology Research Journal, 2022
Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [
Hany Mohammed Ibrahim, Faten Roshdy Abdel-Ghaffar, Ahmed Bahgat Zied, Sameha Husni El-Ghareeb   +3 more
doaj   +1 more source

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam. [PDF]

J Viral Hepat
ABSTRACT People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low‐ and middle‐income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high‐risk population.
Laureillard D, Binh NT, Vinh VH, Hong TT, Quillet C, Thanh NTT, Vallo R, Quynh BTN, Moles JP, Oanh KTH, Huong DT, Rapoud D, Feelemyer J, Michel L, Vickerman P, Fraser H, Weiss L, Lemoine M, Lacombe K, Jarlais DD, Khue PM, Nagot N.   +21 more
europepmc   +2 more sources